Treatment of Epstein-Barr virus-associated malignancies with specific T cells

Advances in Cancer Research

Volumn 84, Issue , 2002, Pages 175-201

  Gottschalk, Stephen ^a,b   Heslop, Helen E ^a,b   Rooney, Cliona M ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; VIRUS PROTEIN;

BURKITT LYMPHOMA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT VIRUS INFECTION; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; NASOPHARYNX CARCINOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; VIRUS LATENCY;

EID: 0036189723     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(02)84006-4     Document Type: Review

References (111)

1. Phenotypic analysis of antigen-specific T lymphocytes
2. Primary central nervous system malignant non-Hodgkin's lymphomas from HIV-infected and non-infected patients: Expression of cellular surface proteins and Epstein-Barr viral markers
3. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell
4. High levels of Epstein-Barr virus DNA in blood of solidorgan transplant recipients and their value in predicting posttransplant lymphoproliferative disorders
5. EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function
6. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia
7. Cell therapy: Achievements and perspectives
8. High expression of latent membrane protein 1 of Epstein-Barr virus and BCL-2 oncoprotein in acquired immunodeficiency syndrome-related primary brain lymphomas
9. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia
10. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation
11. Epstein-Barr virus infection
12. Autologous EBV-specific cytotoxic T cells to treat EBV-associated post-transplant lymphoproliferative disease (PTLD)
13. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study
14. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy
15. Therapy of B-cell lymphoma with antiCD20 antibodies can result in the loss of CD20 antigen expression
16. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leucocytes
17. Virus particles in cultured lymphoblasts from Burkitt's lymphoma
18. Protection of cotton top against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine
19. The ins and outs of EBV infection
20. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation
21. Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma: Case-control and historical cohort studies
22. CD40 cross-linking enhances the immunogenicity of Burkitt's-lymphoma cell lines
23. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to the LMP2A-antigen: A potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma
24. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children
25. An Epstein-Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T cell therapy
26. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children
27. Depletion of EBV-infected cells in donor marrow by counterflow elutriation
28. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome
29. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells
30. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: A multicenter phase 1-2 clinical trial
31. Risks of developing EpsteinBarr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants
32. Epstein-Barr virus-latent gene expression and tumor cell phenotype in aquired immunodeficiency syndrome-related non-Hodgkin's lymphoma
33. AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization
34. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients
35. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells
36. High incidence of Epstein-Barr virus genomes in Hodgkin's disease
37. Adoptive immunotherapy of EBV lymphoproliferative diseases
38. Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease
39. Donor T cells to treat EBV-associated lymphoma
40. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
41. Epstein-barr virus-associated malignancies: Epidemiologic patterns and etiologic implications
42. Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD)
43. HLA-A alleles of patients with pyothorax-associated lymphoma: Anti-Epstein-Barr virus (EBV) host immune responses during the development of EBV latent antigen-positive lymphomas
44. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: Cell phenotype dependence of virus promoter usage
45. Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations
46. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
47. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes
48. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells
49. Vaccine strategies against Epstein-Barr virus-associated diseases: Lessons from studies on cytotoxic T-cell-mediated immune regulation
50. Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: A critical role for antigen expression
51. Deletions within the LMP1 oncogene of EBV are clustered in Hodgkin's disease and identical to those observed in nasophayngeal carcinoma
52. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
53. CTL control of EBV in nasopharyngeal carcinoma, (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells
54. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: Analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-barr virus-specific cytotoxic T-cell recognition
55. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1
56. A perspective on monoclonal antibody therapy: Where we have been and where we are going
57. Addition of B cell depletion of donor marrow with anti-CD20 antibody to a T cell depletion regimen for prevention of EBV Lymphoma after bone marrow transplant
58. Semiquantitative Epstein-Barr virus, (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation
59. Monoclonal antibodies in lymphoid neoplasia: Principles for optimal combined therapy
60. IDEC-C2B8, (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
61. Humanized anti-CD20 monoclonal antibody, (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
62. An animal model for acute and persistent Epstein-Barr virus infection
63. Strategies involved in developing an effective vaccine for EBV-associated diseases
64. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1
65. Analysis of ajor histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease
66. Donor lymphocyte transfusion for the treatment of Epstein-Barr virusassociated lymphoproliferative disorder of the brain
67. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients
68. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study
69. Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease
70. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation
71. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts
72. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts
73. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features
74. Feasibility of cellular adoptive immunotherapy for Epstein-Barr virus-associated lymphomas using haploidentical donors
75. BHRF1, the Epstein-Barr virus (EBV) homologue of the BCL-2 protooncogene, is transcribed in EBV-associated B-cell lymphomas and in reactive lymphocytes
76. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease
77. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
78. Immune escape mechanisms in Hodgkin's disease
79. Acquired immunodeficiency syndrome-related lymphomas: Future directions
80. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: A new modality for vaccination
81. Human cytotoxic T lymphocyte responses to EpsteinBarr virus infection
82. T-cell therapy of cytomegalovirus and human immunodeficiency virus infection
83. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
84. Early identification of Epstein-Barr virus-associated post-transplant lymphoproliferative disease
85. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
86. Pediatric solid-organ transplant recipients carry chronic loads of Epstein-Barr virus exclusively in the immunoglobulin D-negative B-cell compartment
87. EBV-specific cytotoxic T lymphocytes for the treatment of patients with EBV positive relapsed Hodgkin's disease
88. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders
89. Epstein-Barr virus-associated lymphoproliferative disorder after unrelated bone marrow transplantation in a young child with Wiskott-Aldrich syndrome
90. B cell lymphoproliferative disorders following T cell depleted allogeneic bone marrow transplantation
91. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma
92. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients
93. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease
94. Presentation of epstein-barr virus latency antigens to CD8(+), interferon-gamma-secreting
95. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers
96. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease
97. A model for persistent infection with Epstein-Barr virus: The stealth virus of human B cells
98. Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation
99. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft
100. Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state
101. Dysfunctional Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDSrelated non-Hodgkin lymphoma
102. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma
103. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
104. Adoptive immunotherapy using autologous EBV-specific CTL in a HIV infected patient with refractory Epstein-Barr virus expressing B cell lymphoma
105. The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines
106. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens
107. Epstein-Barr virusinfected B cells persist in the circulation of acyclovir-treated virus carriers
108. The Esptein-Barr virus: Host balance in acute infectious mononucleosis patients receiving acyclovir anti-viral therapy
109. The expression and function of Epstein-Barr virus encoded latent genes